$ACAD
ACADIA PHARMACEUTICALS INC

2015 Q2 Form 10-Q Financial Statement

#000119312515177138 Filed on May 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $1.000K $4.000K $30.00K
YoY Change -96.43% -86.67% -92.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $21.10M $24.30M $6.300M
YoY Change 163.75% 285.71% 186.36%
% of Gross Profit
Research & Development $18.38M $16.30M $11.67M
YoY Change 33.19% 39.66% 163.39%
% of Gross Profit
Depreciation & Amortization $280.0K $122.0K $43.00K
YoY Change 460.0% 183.72% 258.33%
% of Gross Profit
Operating Expenses $39.50M $40.56M $17.99M
YoY Change 81.59% 125.46% 173.33%
Operating Profit -$39.50M -$40.55M -$17.96M
YoY Change 81.82% 125.82% 191.34%
Interest Expense $119.0K $177.0K $130.0K
YoY Change -47.81% 36.15% 217.07%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$39.40M -$40.40M -$17.80M
YoY Change 83.26% 126.97% 191.8%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$39.38M -$40.38M -$17.83M
YoY Change 83.2% 126.47% 191.16%
Net Earnings / Revenue -3937800.0% -1009375.0% -59426.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$392.8K -$403.2K -$191.4K
COMMON SHARES
Basic Shares Outstanding 100.3M shares 100.2M shares 91.35M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $270.8M $297.9M $369.3M
YoY Change -23.61% -19.33% 263.83%
Cash & Equivalents $93.21M $76.42M $96.46M
Short-Term Investments $177.6M $221.5M $272.8M
Other Short-Term Assets $1.100M $1.300M $1.900M
YoY Change -64.52% -31.58% 26.67%
Inventory
Prepaid Expenses $1.893M
Receivables
Other Receivables
Total Short-Term Assets $273.4M $299.9M $372.8M
YoY Change -23.81% -19.56% 262.01%
LONG-TERM ASSETS
Property, Plant & Equipment $1.813M $1.786M $543.0K
YoY Change 262.6% 228.91% 1710.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $333.0K $278.0K $143.0K
YoY Change 200.0% 94.41%
Total Long-Term Assets $2.146M $2.064M $686.0K
YoY Change 251.23% 200.87% 2186.67%
TOTAL ASSETS
Total Short-Term Assets $273.4M $299.9M $372.8M
Total Long-Term Assets $2.146M $2.064M $686.0K
Total Assets $275.5M $302.0M $373.5M
YoY Change -23.35% -19.15% 262.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.916M $2.518M $1.562M
YoY Change 164.13% 61.2% 11.89%
Accrued Expenses $16.46M $14.13M $6.429M
YoY Change 100.61% 119.83% 54.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.38M $16.65M $8.033M
YoY Change 107.5% 107.28% 41.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $300.0K $200.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $340.0K $218.0K $13.00K
YoY Change 1788.89% 1576.92% -99.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.38M $16.65M $8.033M
Total Long-Term Liabilities $340.0K $218.0K $13.00K
Total Liabilities $19.72M $16.87M $8.046M
YoY Change 110.73% 109.66% -65.62%
SHAREHOLDERS EQUITY
Retained Earnings -$577.9M -$538.5M -$423.5M
YoY Change 29.87% 27.16% 13.28%
Common Stock $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 42.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $255.8M $285.1M $365.5M
YoY Change
Total Liabilities & Shareholders Equity $275.5M $302.0M $373.5M
YoY Change -23.35% -19.15% 262.57%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$39.38M -$40.38M -$17.83M
YoY Change 83.2% 126.47% 191.16%
Depreciation, Depletion And Amortization $280.0K $122.0K $43.00K
YoY Change 460.0% 183.72% 258.33%
Cash From Operating Activities -$29.87M -$25.35M -$14.18M
YoY Change 76.02% 78.77% 115.34%
INVESTING ACTIVITIES
Capital Expenditures -$670.0K $988.0K $6.000K
YoY Change 16366.67%
Acquisitions
YoY Change
Other Investing Activities $44.74M $39.46M -$99.11M
YoY Change -166.27% -139.81% 199.52%
Cash From Investing Activities $44.07M $38.47M -$99.11M
YoY Change -165.28% -138.82% 199.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.439M $196.8M
YoY Change -99.27% 94515.38%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.600M 1.440M 198.0M
YoY Change 51.16% -99.27% 95111.54%
NET CHANGE
Cash From Operating Activities -29.87M -25.35M -14.18M
Cash From Investing Activities 44.07M 38.47M -99.11M
Cash From Financing Activities 2.600M 1.440M 198.0M
Net Change In Cash 16.80M 14.56M 84.75M
YoY Change -120.3% -82.82% -314.76%
FREE CASH FLOW
Cash From Operating Activities -$29.87M -$25.35M -$14.18M
Capital Expenditures -$670.0K $988.0K $6.000K
Free Cash Flow -$29.20M -$26.34M -$14.19M
YoY Change 72.07% 85.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
100297426 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96455000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100282416 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100282416 shares
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16651000
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3940000
CY2015Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1015000
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
823598000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2518000
CY2015Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
922000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
285094000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-538518000
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14133000
CY2015Q1 us-gaap Liabilities
Liabilities
16869000
CY2015Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
218000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
10000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
301963000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
278000
CY2015Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
221469000
CY2015Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
746000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1786000
CY2015Q1 us-gaap Assets
Assets
301963000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76424000
CY2015Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
221475000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
79100000
CY2015Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
297478000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1260000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
299899000
CY2015Q1 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
8256000
CY2015Q1 acad Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
20000
CY2015Q1 acad Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11707000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100047331 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 us-gaap Revenues
Revenues
30000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100047331 shares
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15834000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4167000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
340000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
807631000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2016000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1497000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
309489000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-498143000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13818000
CY2014Q4 us-gaap Liabilities
Liabilities
15969000
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
135000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
325458000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
287000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
260632000
CY2014Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
964000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
553000
CY2014Q4 us-gaap Assets
Assets
325458000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61854000
CY2014Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
260647000
CY2014Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
322055000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1168000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
324618000
CY2014Q4 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
7814000
CY2014Q4 acad Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2014Q4 acad Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
32000
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7360000 shares
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
196800000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14182000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
92968000 shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9645000 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-48000
CY2014Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-36000
CY2014Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
150921000
CY2014Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
130000
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
892000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
73000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17876000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-17958000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-17828000
CY2014Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-311000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
198042000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6320000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
84748000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-99112000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
17988000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-13000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-123000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1190000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
198042000
CY2014Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
5000
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
51815000
CY2014Q1 us-gaap Depreciation
Depreciation
43000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3162000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11668000
CY2015Q1 dei Trading Symbol
TradingSymbol
ACAD
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001070494
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-25346000
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100197000 shares
CY2015Q1 us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>9. Recent Accounting Pronouncements</b></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In April 2015, the Financial Accounting Standards Board issued authoritative guidance related to accounting for fees paid in a cloud computing arrangement. This accounting update provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual reporting periods beginning after December&#xA0;15, 2015 and early adoption is permitted. The Company adopted this guidance in the first quarter of fiscal 2015 with no significant impact to its consolidated financial statements.</p> </div>
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10855000 shares
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
CY2015Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
367000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
988000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2015Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-9000
CY2015Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
49646000
CY2015Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
177000
CY2015Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4000
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-218000
CY2015Q1 us-gaap Revenues
Revenues
4000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
92000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40362000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-40552000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-40375000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
289000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1439000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24261000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
14570000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
38473000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
40556000
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
4000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
42000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
408000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1439000
CY2015Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
83000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
89107000
CY2015Q1 us-gaap Depreciation
Depreciation
122000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14528000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16295000

Files In Submission

Name View Source Status
0001193125-15-177138-index-headers.html Edgar Link pending
0001193125-15-177138-index.html Edgar Link pending
0001193125-15-177138.txt Edgar Link pending
0001193125-15-177138-xbrl.zip Edgar Link pending
acad-20150331.xml Edgar Link completed
acad-20150331.xsd Edgar Link pending
acad-20150331_cal.xml Edgar Link unprocessable
acad-20150331_def.xml Edgar Link unprocessable
acad-20150331_lab.xml Edgar Link unprocessable
acad-20150331_pre.xml Edgar Link unprocessable
d899508d10q.htm Edgar Link pending
d899508dex101.htm Edgar Link pending
d899508dex102.htm Edgar Link pending
d899508dex311.htm Edgar Link pending
d899508dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending